Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.
GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.
| Conference Call Details | |
| Date: | Friday, March 27 |
| Time: | 8:30 am Eastern Time |
| Domestic: | 877-423-9813 |
| International: | 201-689-8573 |
| Conference ID: | 13701071 |
| Webcast: | http://public.viavid.com/index.php?id=138792 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVIDTM). For more information on Altimmune, please visit www.altimmune.com.
| Contacts: | |
| Will Brown | Ashley R. Robinson |
| Chief Financial Officer | LifeSci Advisors, LLC |
| Phone: 240-654-1450 | 617-430-7577 |
| wbrown@altimmune.com | arr@lifesciadvisors.com |
